Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

PubWeight™: 35.17‹?› | Rank: Top 0.01% | All-Time Top 10000

🔗 View Article (PMID 11583749)

Published in Lancet on September 22, 2001

Authors

M P Manns1, J G McHutchison, S C Gordon, V K Rustgi, M Shiffman, R Reindollar, Z D Goodman, K Koury, M Ling, J K Albrecht

Author Affiliations

1: Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany. manns.michael@mh-hannover.de

Associated clinical trials:

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV | NCT00225537

Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients | NCT00495131

Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR | NCT00532701

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation (LADR) | NCT00135798

12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy. | NCT00069511

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred1) | NCT01434212

Effect Of DAAs For Treatment Of HCV On Normal Kidney | NCT03296930

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) (sIFN-pred2) | NCT01760148

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 | NCT00575224

Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan | NCT00543244

Reducing Depressive Symptoms During HCV Therapy: A Randomized Study | NCT00495768

Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection | NCT00248339

Articles citing this

(truncated to the top 100)

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67

Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med (2011) 6.69

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87

Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84

Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med (2009) 3.72

Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71

Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43

Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol (2007) 3.04

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83

Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother (2006) 2.75

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol (2003) 2.74

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61

An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol (2005) 2.52

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48

Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45

Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 2.44

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2006) 2.42

Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut (2005) 2.38

Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut (2005) 2.35

Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe (2009) 2.33

Rate and predictors of treatment prescription for hepatitis C. Gut (2006) 2.31

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol (2005) 2.30

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24

The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22

Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22

Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20

Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19

Hepatitis C treatment completion rates in routine clinical care. Liver Int (2009) 2.10

Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08

Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc (2009) 2.07

Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06

The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06

Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics (2009) 2.02

Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol (2009) 2.00

Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97

Hepatitis C. Lancet (2015) 1.95

Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol (2013) 1.89

Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J (2006) 1.89

Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89

Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87

An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol (2007) 1.85

Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85

Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology (2008) 1.85

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut (2004) 1.85

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84

Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84

Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol (2006) 1.84

Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol (2007) 1.82

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78

Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis (2010) 1.75

Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74

Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. J Clin Microbiol (2004) 1.74

Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol (2006) 1.74

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut (2003) 1.74

Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69

Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A (2010) 1.67

Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66

Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2007) 1.66

Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol (2011) 1.63

Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut (2003) 1.61

Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61

Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis (2006) 1.61

Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60

Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut (2006) 1.59

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58

Higher clearance of hepatitis C virus infection in females compared with males. Gut (2006) 1.57

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57

The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol (2008) 1.57

Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother (2008) 1.56

Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55

Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat (2014) 1.54

Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54

Articles by these authors

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23

Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84

Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74

Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer (1999) 3.68

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02

Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99

NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94

Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol (1984) 2.79

Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol (1994) 2.72

A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med (1994) 2.71

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest (2001) 2.61

The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med (1992) 2.40

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38

Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2014) 2.22

Mumps arthritis: unusual presentation as adult Still's disease. Ann Intern Med (1982) 2.21

American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology (2006) 2.14

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13

Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology (1991) 2.12

Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol (1996) 2.10

Eosinophilic granuloma of the liver: a characteristic lesion with relationship to visceral larva migrans. Am J Surg Pathol (2001) 2.07

Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults. Am J Surg Pathol (2000) 1.95

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology (1999) 1.90

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat (2007) 1.89

Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer (1985) 1.82

Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res (2001) 1.75

Xanthogranulomatous cholecystitis. Am J Surg Pathol (1981) 1.70

Association of hepatocellular carcinoma in North American patients with extrahepatic primary malignancies. Cancer (1994) 1.69

Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med (1986) 1.67

Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol (1996) 1.62

Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat (2009) 1.62

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut (2003) 1.61

Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57

Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med (1986) 1.56

LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol (2000) 1.54

Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med (1992) 1.51

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol (2001) 1.50

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology (2000) 1.49

Ciliated hepatic foregut cyst: a study of six cases and review of the literature. Am J Surg Pathol (1999) 1.48

Hyperthyroidism and hepatic dysfunction. A case series analysis. J Clin Gastroenterol (1992) 1.45

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat (2000) 1.45

Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol (2001) 1.44

Malignant vascular tumors of the liver: radiologic-pathologic correlation. Radiographics (1994) 1.43

Squamous cell carcinoma arising in a ciliated hepatic foregut cyst. Arch Pathol Lab Med (1999) 1.42

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41

Undifferentiated (embryonal) sarcoma of the liver: pathologic basis of imaging findings in 28 cases. Radiology (1997) 1.40

The so-called bile duct adenoma is a peribiliary gland hamartoma. Am J Surg Pathol (1996) 1.40

Biliary cystadenoma and cystadenocarcinoma: clinical-imaging-pathologic correlations with emphasis on the importance of ovarian stroma. Radiology (1995) 1.39

A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. Am J Clin Pathol (1992) 1.39

Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol (2001) 1.38

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Hepatology (1997) 1.38

Comparative histologic features of liver biopsy specimens from patients coinfected with hepatitis G and C viruses with chronic hepatitis C virus alone: an age-, sex-, disease duration-, and transmission-matched controlled study of chronic hepatitis. Am J Clin Pathol (1997) 1.38

A General Theorem on Conformal Mapping of Multiply Connected Domains. Proc Natl Acad Sci U S A (1940) 1.38

Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med (1986) 1.31

Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis (1986) 1.30

Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection. J Infect Dis (1985) 1.29

Influenza B in households: virus shedding without symptoms or antibody response. Am J Epidemiol (1987) 1.29

Tattoo application is not associated with an increased risk for chronic viral hepatitis. Am J Gastroenterol (2000) 1.28

Angiomyolipomas of the liver. Am J Surg Pathol (1984) 1.28

Mesenchymal hamartoma of the liver: radiologic-pathologic correlation. Radiology (1986) 1.26

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother (1988) 1.25

Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.22

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat (1996) 1.21

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am J Gastroenterol (2000) 1.21

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology (2000) 1.21

Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol (1993) 1.19

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (1997) 1.17

The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther (2014) 1.14

Spectrum of hepatitis E virus infection in India. J Med Virol (1994) 1.12

Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol (1998) 1.11

Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics (1999) 1.11

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 1.11

Postinfantile giant-cell transformation in hepatitis. Hepatology (1992) 1.09

Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol (2001) 1.08

Thorotrast-induced hepatosplenic neoplasia: CT identification. AJR Am J Roentgenol (1986) 1.08

Assessment of hepatitis B virus DNA and hepatitis C virus RNA in the common bedbug (Cimex lectularius L.) and kissing bug (Rodnius prolixus). Am J Gastroenterol (2001) 1.08

Hypercontractile cardiac states simulating hypertrophic cardiomyopathy. Circulation (1977) 1.08

Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med (1984) 1.08

Intrahepatic cholangiocarcinoma: radiologic-pathologic correlation. Radiology (1988) 1.08

Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2015) 1.07

Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 1.07

Hemangiomas with localized nodular proliferation of the liver. A suggestion on the pathogenesis of focal nodular hyperplasia. Am J Surg Pathol (1990) 1.07

Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol (1996) 1.07

Nodular regenerative hyperplasia of the liver: clinical and radiologic observations. AJR Am J Roentgenol (1987) 1.06

Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res (2001) 1.06

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat (2010) 1.06

Solitary fibrous tumor of the liver: a clinicopathologic and immunohistochemical study of nine cases. Ann Diagn Pathol (1998) 1.06